210 related articles for article (PubMed ID: 30914801)
1. FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis.
Seshacharyulu P; Rachagani S; Muniyan S; Siddiqui JA; Cruz E; Sharma S; Krishnan R; Killips BJ; Sheinin Y; Lele SM; Smith LM; Talmon GA; Ponnusamy MP; Datta K; Batra SK
Oncogene; 2019 Jun; 38(26):5265-5280. PubMed ID: 30914801
[TBL] [Abstract][Full Text] [Related]
2. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
Liao CP; Lin TP; Li PC; Geary LA; Chen K; Vaikari VP; Wu JB; Lin CH; Gross ME; Shih JC
Oncogene; 2018 Sep; 37(38):5175-5190. PubMed ID: 29844571
[TBL] [Abstract][Full Text] [Related]
3. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
[No Abstract] [Full Text] [Related]
4. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
5. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
6. LncRNA PlncRNA-1 accelerates the progression of prostate cancer by regulating PTEN/Akt axis.
Cui Z; Gao H; Yan N; Dai Y; Wang H; Wang M; Wang J; Zhang D; Sun P; Qi T; Wang Q; Kang W; Jin X
Aging (Albany NY); 2021 Apr; 13(8):12113-12128. PubMed ID: 33848262
[TBL] [Abstract][Full Text] [Related]
7. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling.
Seshacharyulu P; Halder S; Nimmakayala R; Rachagani S; Chaudhary S; Atri P; Chirravuri-Venkata R; Ouellette MM; Carmicheal J; Gautam SK; Vengoji R; Wang S; Li S; Smith L; Talmon GA; Klute K; Ly Q; Reames BN; Grem JL; Berim L; Padussis JC; Kaur S; Kumar S; Ponnusamy MP; Jain M; Lin C; Batra SK
EBioMedicine; 2022 Jan; 75():103772. PubMed ID: 34971971
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer.
Nip H; Dar AA; Saini S; Colden M; Varahram S; Chowdhary H; Yamamura S; Mitsui Y; Tanaka Y; Kato T; Hashimoto Y; Shiina M; Kulkarni P; Dasgupta P; Imai-Sumida M; Tabatabai ZL; Greene K; Deng G; Dahiya R; Majid S
Oncotarget; 2016 Oct; 7(42):68371-68384. PubMed ID: 27634912
[TBL] [Abstract][Full Text] [Related]
9. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
10. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.
Jefferies MT; Cox AC; Shorning BY; Meniel V; Griffiths D; Kynaston HG; Smalley MJ; Clarke AR
J Pathol; 2017 Dec; 243(4):442-456. PubMed ID: 29134654
[TBL] [Abstract][Full Text] [Related]
11. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.
Ding X; Xu X; He XF; Yuan Y; Chen C; Shen XY; Su S; Chen Z; Xu ST; Huang YH
Bioengineered; 2021 Dec; 12(1):803-814. PubMed ID: 33648424
[TBL] [Abstract][Full Text] [Related]
12. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
13. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
[TBL] [Abstract][Full Text] [Related]
14. Farnesyl diphosphate synthase regulated endothelial proliferation and autophagy during rat pulmonary arterial hypertension induced by monocrotaline.
Jin T; Lu J; Lv Q; Gong Y; Feng Z; Ying H; Wang M; Fu G; Jiang D
Mol Med; 2022 Aug; 28(1):94. PubMed ID: 35962329
[TBL] [Abstract][Full Text] [Related]
15. Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.
Wang Z; Xu D; Ding HF; Kim J; Zhang J; Hai T; Yan C
Oncogene; 2015 Sep; 34(38):4975-84. PubMed ID: 25531328
[TBL] [Abstract][Full Text] [Related]
16. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
17. Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
Bjerke GA; Yang CS; Frierson HF; Paschal BM; Wotton D
Oncogene; 2014 Jul; 33(28):3660-7. PubMed ID: 23995785
[TBL] [Abstract][Full Text] [Related]
18. miR-92a promotes proliferation and inhibits apoptosis of prostate cancer cells through the PTEN/Akt signaling pathway.
Yanshen Z; Lifen Y; Xilian W; Zhong D; Huihong M
Libyan J Med; 2021 Dec; 16(1):1971837. PubMed ID: 34431444
[TBL] [Abstract][Full Text] [Related]
19. Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway.
Kong L; Schäfer G; Bu H; Zhang Y; Zhang Y; Klocker H
Carcinogenesis; 2012 Apr; 33(4):751-9. PubMed ID: 22301279
[TBL] [Abstract][Full Text] [Related]
20. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
